2024 Abstracts Now Available to View
Abstract Deadlines
- Abstract submission deadline: October 9, 2023
- Abstract accept/reject notification: December 1, 2023
- Late breaking abstract submissions: December 4 – 18, 2023
- Late-breaking accept/reject notification: January 9, 2024
Late-Breaking Abstracts
The submission of late-breaking abstracts will open December 4 and close on December 18, 2023 at 11:59 PM CT.
Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program Co-Chairs.
Abstract Eligibility
Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission. Data that has been, or will be, presented at any other meeting before being presented at the 2024 Tandem Meetings of ASTCT and CIBMTR, will not be accepted for presentation.
Due to the overlap in abstract submission and notification timelines for the 2023 ASH Annual Meeting, data submitted to the 2023 ASH Annual Meeting is acceptable for submission to the 2024 Tandem Meetings of ASTCT and CIBMTR. However, abstracts that are accepted and presented at other meetings, including ASH 2023, will not be considered for Tandem Best Abstract Awards, unless an exception is granted by the Scientific Co-Chairs. All submitted abstracts will be reviewed by the Tandem Meetings Scientific Organizing Committee, which has discretion to decide if an abstract presented at the 2023 ASH Meeting will be eligible for presentation at the 2024 Tandem Meetings.
Conference Registration Fee
Abstract presenting authors will be eligible for the early registration rate even after standard and on-site registration rates apply.
Abstract Submission Fee
There is a $50 non-refundable abstract submission fee.
Abstract Categories
Abstract data/research must apply to one of the following categories:
- Acute and chronic leukemia (AML, MDS, MPD ALL, CML) - Basic/preclinical
- Acute and chronic leukemia (AML, MDS, MPD ALL, CML) - Clinical
- Acute Regimen-Related Toxicity and Supportive Care
- Autoimmune Disorders: Transplant and Effector Cells
- Cellular and Gene therapy: Regulatory & Processing
- Conditioning regimens
- Donor Safety, Unique Mobilizations, & Health Services
- Engineered Immune Cells (CAR-T, NK, TCR): Basic/Preclinical - Antigen Finding, Safety
- Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies
- Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Solid Tumors
- Gene Therapy and Editing
- Graft Sources (related, matched and mismatched unrelated, haplo, autologous, cord blood, bone marrow and peripheral blood)
- Graft-versus-Host and graft versus tumor - Basic/preclinical
- Graft-versus-Host and graft versus tumor - Clinical: Prevention, treatment and biomarkers
- Hematopoietic stem cell niche, biology, expansion & Marrow Failure Syndromes
- Hemoglobinopathies, Primary Immune Deficiencies and Disregulation, and Inborn Errors of Immunity
- HSCT, gene and other cellular therapies in countries with constrained resources
- Immune reconstitution and Immunobiology
- Immunogenetics
- Infectious Diseases and Cytotoxic T Lymphocytes
- Intersectionality, Diversity, and Inclusion & Removing Barriers to Access in TCT
- Late Effects, Quality of Life, and Accelerated Aging
- Lymphoma/CLL - Basic/Preclinical
- Lymphoma/CLL - Clinical
- Myeloma - Basic/Preclinical
- Myeloma - Clinical
- Relapse - Basic/preclinical
- Relapse - Clinical: Prevention and Treatment
- Study design and statistics
- Transplant and Cell Therapy for Aged and Geriatric Populations
- Advanced Practice Professionals (for Advance Practice Provider Track)
- IT and Informatics for Transplant and Cellular Therapy (CIBMTR)
- Quality and Transplant Program Administration (for Administrative Director Track)
- Transplantation Data Management (for Clinical Research Professionals/Data Managers Track)
- Transplantation Pharmacology (for Pharmacists Track)
Nursing Track Abstract Categories
- Administration
- Clinical
- Education
- Research
Responsibility of Abstract Authors
- Ensuring that all authors have read the abstract and agreed to be co-authors.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the Tandem Meetings of ASTCT and CIBMTR.
- Obtaining all of the conflict-of-interest disclosure information from co-authors.
- Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar, or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
- Ensuring that they will be prepared to present and to respond to questions regarding the abstract. If that is not the case, the authors should choose a poster as their preference.
- Have read all of the rules and agrees to be bound by them.
- Are responsible for submission of the abstract in accordance with the rules, and waives any and all claims against ASTCT/CIBMTR/Tandem Meetings of ASTCT and CIBMTR and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Abstract Review
Abstracts are peer reviewed on their scientific merits and according to subject category. Individuals submitting abstracts must indicate the appropriate review category. Abstracts may be re-categorized to a more appropriate category based on guidance from the Tandem Meetings Co-Chairs. The ASTCT, CIBMTR and Tandem Meetings of ASTCT and CIBMTR reserve the right to make minor editorial grammatical/spelling changes if required for clarity of presentation.
Abstract Corrections
All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. Requests for assistance in accessing abstracts to allow for modifications, should be submitted in writing to tandemabstracts@astct.org.
Late-Breaking Abstract Withdrawals
Abstract withdrawals can be made within the submission system by the first author, no later than Monday, December 18 at 11:59 PM CT.
Abstract withdrawal requests after December 18 must be made, in writing only, to tandemabstracts@astct.org. ASTCT and CIBMTR Staff cannot fulfill any withdrawal requests by phone. Accepted abstracts that remain in the submission system on January 15, 2024, may be published online and in ASTCT's journal, Transplantation and Cellular Therapy, as submitted.
Incomplete Late-Breaking Abstracts
Any submitted abstract deemed incomplete within the submission system on Monday, December 18 at 11:59 PM CT will be eliminated without further notification prior to abstracts being distributed to the 2024 Tandem Meetings abstract Abstract Review Committee.
Embargo
Abstracts submitted for presentation will be embargoed by the author(s) and the 2024 Tandem Meetings, upon submission.
Abstracts submitted for presentation to the 2024 Tandem Meetings will be embargoed by the author(s) and the 2024 Tandem Meetings, upon submission. The embargo will be lifted and abstracts will be made available for viewing on January 17, 2024.
Late breaking abstracts will be subject to a separate embargo timeline and will be available for viewing on February 14, 2024.
Copyright
Authors assign copyright of the abstract to ASTCT upon submission, unless one of the authors is a U.S. Federal employee. This means that the identical abstract may not be republished or submitted to another meeting; however, Elsevier may grant permission for reuse of abstract content on behalf of ASTCT. You can request to re-use an abstract by clicking here.
Social Media
ASTCT
CIBMTR
#Tandem25
